Stanford Graduate School of Business (USA)
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems - Teaching Note
Chess, R; Luthre, JTeaching Note SGSB-E489TN-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €0.00
-
Waste Management's Organic Growth Group
Burgelman, R; Siegel, R; Uribe, TCase SGSB-SM210-EStrategyIt was 2005 and David Steiner, CEO of Waste Management (WM), had just received a report from an internal advisory panel created some months before to assess the future of the waste management industry and propose how the company’s strategy should be adapted. The core of this report was the recommendation to create a special unit within the company, chartered with the central purpose of identifying ways to extract value from waste through new and ...Starting at €8.20
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems
Chess, R; Luthre, JCase SGSB-E489-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €8.20